From LSE5 Apr 2020 10:32
NCYT has a long way to run and will sell every kit produced. It says is has committed to purchasing enough materials for 187,500 kits or 18m tests which I believe equates to £156m, how much is profit I don’t know. That excludes what the OEM in the US is producing and I’m really looking forward to that update.
That said a lot will happen domestically and quickly.
Some content to the gov’s approach -
Pillar 5: Spearheading a Diagnostics National Effort to build a mass-testing capacity at a completely new scale
1.29 Britain has an innovative, but relatively small diagnostics industry. We now need to grow it, substantially and quickly. We are calling on all British life science companies to turn their resources to creating and rolling out mass testing at scale. In the short-term, this will help meet the supply outlined in the other strands in this strategy, and then help us develop resilient, diagnostic capability in the UK capable of meeting the testing demands over the coming months and years.
(b) The solutions must enable testing at huge scale, but with extremely high levels of accuracy and sensitivity. An unreliable test is worse than no test.
(c) It needs to be resilient - the end to end supply chain for the test should be domestically based as far as practically possible, with a clear and deliverable plan for the capacity and capability to deliver the scale of testing we need.
.31 We have already asked industry to tell us if they can manufacture testing equipment or consumables; or if they have new or existing complete tests. We are particularly focused on local manufacturers who can offer reagents and other consumables - and these offers will be prioritised. We will continue to issue calls over the coming days and weeks - these will be asks on specific areas where we need current capability to be ramped up. We will also issue more detail on how we are working with industry to grow our national diagnostic industry.
1.32 We are already working with our multinational companies; small, innovative manufacturers; and industry bodies. Over the coming days, we will ramp up this engagement further, working with many others to develop this national effort
Finally, we are going to continue rapidly building a diagnostics industrial strategy that will develop our manufacturing capabilities, to secure the stable supply of the tests, equipment and consumables we need for mass-testing at scale over the immediate and medium term.
Sign In
Follow the stocks
